Complete Filing Data
Predictmedix Inc. reported Number Of Shares Outstanding of 122.05 million shares for FY2023.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Predictmedix Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2023 | FY2022 | FY2021 |
|---|---|---|---|
| Sales And Marketing Expense | $294.1K | $508.6K | $221.7K |
| Research And Development Expense | $82.6K | $72.9K | $26.3K |
| Profit Loss Attributable To Owners Of Parent | -$2.1M | -$1.9M | -$1.6M |
| Profit Loss Attributable To Noncontrolling Interests | $0.00 | $0.00 | -$2.8K |
| Profit Loss | -$2.1M | -$1.9M | -$1.6M |
| Income Taxes Paid Refund | $0.00 | $0.00 | $0.00 |
| Gross Profit | $26.6K | $84.8K | $0.00 |
| General And Administrative Expense | $89.4K | $33.3K | $13.7K |
| Cost Of Sales | $8.4K | $50.0K | $0.00 |
| Profit Loss From Discontinued Operations | $0.00 | $346.3K | |
| Interest Expense | $2.9K | $0.00 | |
| Income Tax Expense Continuing Operations | $0.00 | $0.00 |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2023 | FY2022 | FY2021 |
|---|---|---|---|
| Trade And Other Current Payables | $833.3K | $334.5K | $135.4K |
| Retained Earnings | -$8.1M | -$6.0M | -$4.1M |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | $94.8K | $84.8K | $0.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | $49.9K | $333.4K | $195.0K |
| Property Plant And Equipment | $134.5K | $76.3K | $8.2K |
| Liabilities | $871.1K | $349.7K | $135.4K |
| Intangible Assets Other Than Goodwill | $445.7K | $518.8K | $248.0K |
| Equity And Liabilities | $717.7K | $1.2M | $1.0M |
| Current Value Added Tax Receivables | $26.0K | $211.5K | $112.0K |
| Current Trade Receivables | $12.5K | $169.5K | $0.00 |
| Current Deferred Income Other Than Current Contract Liabilities | $0.00 | $15.2K | $0.00 |
| Current Assets | $137.5K | $641.6K | $747.4K |
| Cash Flows From Used In Operating Activities | -$534.2K | -$1.5M | -$1.1M |
| Cash Flows From Used In Investing Activities | -$144.7K | -$418.1K | -$195.0K |
| Cash Flows From Used In Financing Activities | $546.8K | $1.7M | $261.1K |
| Cash And Cash Equivalents | $79.3K | $211.3K | $480.1K |
| Assets | $717.7K | $1.2M | $1.0M |
| Adjustments For Increase Decrease In Trade Account Payable | $498.8K | $199.1K | $68.8K |
| Adjustments For Increase Decrease In Deferred Income Other Than Contract Liabilities | -$15.2K | $15.2K | $0.00 |
| Adjustments For Decrease Increase In Trade Account Receivable | $157.0K | -$169.5K | $0.00 |
| Adjustments For Decrease Increase In Sales Tax Receivable | $185.5K | -$99.5K | -$101.8K |
| Promissory Notes Payable Current | $37.9K | $0.00 |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2023 | FY2022 | FY2021 |
|---|---|---|---|
| Proceeds From Issuing Other Equity Instruments | $495.0K | $1.1M | $0.00 |
| Proceeds From Exercise Of Options | $0.00 | $595.3K | $213.3K |
| Payments For Share Issue Costs | $33.2K | $3.8K | $0.00 |
| Increase Decrease In Cash And Cash Equivalents | -$132.1K | -$268.7K | -$1.0M |
| Proceeds From Exercise Of Warrants | $0.00 | $50.0K | |
| Proceeds From Borrowings Classified As Financing Activities | $35.0K | $0.00 | |
| Payments Of Lease Liabilities Classified As Financing Activities | $0.00 | $2.1K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|
| Number Of Shares Outstanding | 122.1M | 109.1M | 101.7M | 104.1M |
| Weighted Average Shares | 114.2M | 107.9M | 101.2M | |
| Shares Issued For Prepayment And Expense For Consulting Fees | 165.0K | 36.3K | 20.0K | |
| Increase Decrease Through Shares Issued For Consulting Services Shares | 3.1M | 250.0K | 58.8K | |
| Increase Decrease Through Shares Issued For Consulting Services | 165.0K | 36.3K | 20.0K | |
| Diluted Earnings Loss Per Share | $-0.02 | $-0.02 | $-0.02 | |
| Adjustments For Shares Issued For Consulting Services | 165.0K | 36.3K | 8.3K | |
| Shares Issued For Acquisition Of Intangible Assets | 0.00 | 53.0K |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2023 | FY2022 | FY2021 |
|---|---|---|---|
| Warrant Reserve | $596.9K | $510.5K | $115.8K |
| Wages And Salaries | $115.9K | $165.3K | $0.00 |
| Travel Expense | $11.3K | $33.6K | $31.3K |
| Transportation Expense | $36.0K | $36.0K | $22.5K |
| Transfer Agent And Filing Fees | $65.6K | $51.2K | $57.9K |
| Reserve Of Sharebased Payments | $1.0M | $675.6K | $853.8K |
| Rental Expense | $35.9K | $32.1K | $21.5K |
| Professional Fees Expense | $351.9K | $175.7K | $178.0K |
| Operating Expense | $2.1M | $2.0M | $1.9M |
| Legal Fees | $94.8K | $192.6K | $138.9K |
| Issued Capital | $6.3M | $5.7M | $4.0M |
| Investor Relations | $51.9K | $99.3K | $0.00 |
| Increase Decrease Through Sharebased Payment Transactions | $350.6K | $183.0K | $946.4K |
| Expense From Sharebased Payment Transactions With Employees | $350.6K | $183.0K | $946.4K |
| Current Prepaid Expenses | $19.7K | $49.3K | $155.4K |
| Auditors Remuneration For Audit Services | $70.1K | $34.0K | $38.6K |
| Administrative Expense | $282.0K | $269.8K | $217.1K |
| Adjustments For Sharebased Payments | $350.6K | $183.0K | $946.4K |
| Adjustments For Depreciation And Amortisation Expense | $159.5K | $79.3K | $3.5K |
| Adjustments For Decrease Increase In Prepaid Expenses | $29.6K | $106.1K | -$45.0K |
| Share Issue Related Cost | $33.2K | $3.8K | |
| Increase Decrease Through Private Placement Of Units Shares | 9.9M | 3.1M | |
| Increase Decrease Through Private Placement Of Units | $495.0K | $1.1M | |
| Increase Decrease Through Exercise Of Options Shares | 4.0M | 1.5M | |
| Increase Decrease Through Exercise Of Options | $595.3K | $213.3K | |
| Share Premium | $50.0K | $0.00 | |
| Patent And Trademark Expenses | $0.00 | $13.6K | |
| Depreciation And Amortisation Expense | $159.5K | $79.3K |
Most recent annual filing with the SEC: June 16, 2023
Data sourced from SEC EDGAR public filings as of August 7, 2026.